Exectras says the money will go toward beefing up its merchant portfolios, developing infrastructure, and carrying out organic growth. Photo by Hero Images

Missouri City-based Exectras, a provider of services for small and midsize businesses, has secured debt financing of up to $30 million from Austin-based investment manager Tacora Capital.

Exectras says the money will go toward beefing up its merchant portfolios, developing infrastructure, and carrying out organic growth.

Founded in 2007, Exectras offers an array of discounted business services to small and midsize businesses, including merchant services, payroll, health insurance, and workers’ compensation insurance. In addition, Exectras originates and acquires credit card residuals and merchant portfolios representing billions of dollars in annual processing volume.

“We are grateful to have a partner in Tacora that understands our business and is committed to our growth. As entrepreneurs themselves, they understand how valuable our services can be. We look forward to an extended partnership,” Joseph Cherry, president and CEO of Exectras, says in a news release.

Denver-based SFT Capital arranged the deal.

Last year, Tacora launched its inaugural debt fund, which contains $350 million. Peter Thiel, a billionaire venture from Silicon Valley, is the fund’s main investor. He poured $250 million into the investment vehicle.

Formation of the Tacora fund comes amid a surge in private debt financing. Asset management giant BlackRock forecasts that the global market for private debt will soar to $3.5 trillion by 2028.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.